Defence Research and Development Canada   Report issue

Government Phase 2 Phase 3 Phase 4
Founded: Ottawa Canada (1947)

Organization Overview

First Clinical Trial
2004
NCT01642524
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Brain Injuries (Phase 3)

Brain Injuries, Traumatic (Phase 3)

Craniocerebral Trauma (Phase 3)

Heart Arrest (Phase 3)

Hemorrhage (Phase 3)

Out-of-Hospital Cardiac Arrest (Phase 3)

Shock (Phase 3)

Shock, Traumatic (Phase 3)

Subarachnoid Hemorrhage (Phase 3)

Tachycardia (Phase 3)

Ventricular Fibrillation (Phase 3)

Wounds and Injuries (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 8
  • # of Trial APIs: 9